You are viewing an incomplete version of our website. Please click to reload the website as full version.

TAR DNA Binding Protein (TARDBP) (AA 350-414), (C-Term) antibody

Details for Product No. ABIN188986, Supplier: Log in to see
Antigen
  • TARDBP
  • TDP43
  • DKFZp459I2127
  • tardbp
  • ALS10
  • TDP-43
  • 1190002A23Rik
  • C85084
  • Tdp43
  • wu:fb77f02
  • wu:fc52g10
  • TAR DNA binding protein
  • Tardbp protein
  • TAR DNA-binding protein 43-like
  • TARDBP
  • tardbp
  • Tardbp
  • LOC100621383
Alternatives
anti-Chicken TAR DNA Binding Protein antibody for Immunohistochemistry
Epitope
C-Term, AA 350-414
28
21
19
18
16
15
13
10
8
8
6
6
3
3
2
2
1
1
1
1
1
1
1
Reactivity
Chicken, Human, Mouse (Murine), Primate, Xenopus laevis, Zebrafish
234
126
94
35
28
27
19
16
14
11
11
7
7
6
5
4
1
Host
Rabbit
131
93
17
1
Clonality
Polyclonal
Conjugate
Un-conjugated
10
10
8
6
5
5
5
5
5
4
4
4
3
3
3
3
3
3
3
3
1
1
1
1
1
1
1
1
1
Application
Immunocytochemistry (ICC), Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)
219
113
112
75
49
49
18
15
13
5
4
4
3
3
2
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen A synthetic peptide to a C-terminal region [within residues 350-414] of the human TARDBP protein. [Swiss-Prot# Q13148]
Purification Immunogen affinity purified
Alternative Name TDP-43/TARDBP (TARDBP Antibody Abstract)
Background Gene Symbol: TARDBP
Molecular Weight Theoretical MW: 45 kDa
Gene ID 23435
UniProt Q13148
Pathways Positive Regulation of Peptide Hormone Secretion
Application Notes Western Blot 0.5-2 μg/mL, Immunohistochemistry, Immunocytochemistry/Immunofluorescence 1:100-1:1000This TARDBP antibody is useful for Immunocytochemistry/Immunofluorescence and Western blot analysis. In Western blot a band is seen at ~45 kDa, representing the human TARDBP protein. In ICC/IF a nuclear signal is present in MCF-7 cells. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Comment

The antibodies are intended for use in vitro experiments only. Our antibodies have not been tested nor are recommended for use in vivo.

Protocol Protocol specific for TARDBP Antibody Western Blot Protocol
1. Perform SDS-PAGE (4-12 % Bis-Tris) on samples to be analyzed, loading 20 µg of total protein per lane.
. Transfer proteins to Nitrocellulose according to the instructions provided by the manufacturer of the transfer apparatus.
. Rinse membrane with dH2O and then stain the blot using Ponceau S for 1-2 minutes to access the transfer of proteins onto the nitrocellulose membrane. Rinse the blot in water to remove excess stain and mark the lane locations and locations of molecular weight markers using a pencil.
. Rinse the blot in TBS for approximately 5 minutes.
. Block the membrane using 5 % non-fat dry milk + 1 % BSA in TBS, overnight at 4 degrees Celcius.
. Rinse the membrane in dH2O and then wash the membrane in wash buffer [TBS + 0.1 % Tween] 3 times for 10 minutes each.
. Dilute the rabbit anti-TARDBP primary antibody in blocking buffer and incubate 1 hour at room temperature.
. Rinse the membrane in dH2O and then wash the membrane in wash buffer [TBS + 0.1 % Tween] 3 times for 10 minutes each.
. Apply the diluted rabbit-IgG HRP-conjugated secondary antibody in blocking buffer (as per manufacturersinstructions) and incubate 1 hour at room temperature.
. Wash the blot in wash buffer [TBS + 0.1 % Tween] 3 times for 10 minutes each (this step can be repeated as required to reduce background).
. Apply the detection reagent of choice in accordance with the manufacturers instructions (Pierce ECL).Note: Tween-20 can be added to the blocking or antibody dilution buffer at a final concentration of 0.05-0.2 %, provided it does not interfere with antibody-antigen binding.
Restrictions For Research Use only
Format Liquid
Concentration 1 mg/mL
Buffer Tris-Glycine and 0.15M NaCl
Buffer contains: 0.05 % Sodium Azide
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Do not freeze.
Storage 4 °C
Storage Comment Store at 4°C. Do not freeze.
Supplier Images
Western Blotting (WB) image for anti-TAR DNA Binding Protein (TARDBP) (AA 350-414), (C-Term) antibody (ABIN188986) Detection of TARDBP in HeLa WCE using ABIN188986.
Western Blotting (WB) image for anti-TAR DNA Binding Protein (TARDBP) (AA 350-414), (C-Term) antibody (ABIN188986) Western Blot: TDP-43/TARDBP Antibody [ABIN1889866] - Cells were transfected with the ...
Immunofluorescence (IF) image for anti-TAR DNA Binding Protein (TARDBP) (AA 350-414), (C-Term) antibody (ABIN188986) Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [ABIN1889866] - TARDBP...
Immunofluorescence (IF) image for anti-TAR DNA Binding Protein (TARDBP) (AA 350-414), (C-Term) antibody (ABIN188986) Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [ABIN1889866] - Analys...
Product cited in: Li, Yokoshi, Okada, Kawahara: "The cleavage pattern of TDP-43 determines its rate of clearance and cytotoxicity." in: Nature communications, Vol. 6, pp. 6183, 2015 (PubMed).

Goossens, Vanmechelen, Trojanowski, Lee, Van Broeckhoven, van der Zee, Engelborghs: "TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies." in: Acta neuropathologica communications, Vol. 3, pp. 15, 2015 (PubMed).

Fang, Tsai, Chang, Kao, Woods, Kuo, Wu, Liao, Chou, Lin, Jin, Yuan, Cheng, Tu, Chen: "Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients." in: Nature communications, Vol. 5, pp. 4824, 2014 (PubMed).

Schmid, Hruscha, Hogl, Banzhaf-Strathmann, Strecker, van der Zee, Teucke, Eimer, Hegermann, Kittelmann, Kremmer, Cruts, Solchenberger, Hasenkamp, van Bebber, Van Broeckhoven, Edbauer, Lichtenthaler et al.: "Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. ..." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, Issue 13, pp. 4986-91, 2013 (PubMed). (Sample species: Zebrafish (Danio rerio)). Further details: Western Blotting

Udan-Johns, Bengoechea, Bell, Shao, Diamond, True, Weihl, Baloh: "Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones." in: Human molecular genetics, Vol. 23, Issue 1, pp. 157-70, 2013 (PubMed). (Sample species: Human). Further details: Western Blotting

Kawahara, Mieda-Sato: "TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, Issue 9, pp. 3347-52, 2012 (PubMed).

Mitne-Neto, Machado-Costa, Marchetto, Bengtson, Joazeiro, Tsuda, Bellen, Silva, Oliveira, Lazar, Muotri, Zatz: "Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients." in: Human molecular genetics, Vol. 20, Issue 18, pp. 3642-52, 2011 (PubMed). (Sample species: Human). Further details: Immunocytochemistry,Immunofluorescence

Shiina, Arima, Tabunoki, Satoh: "TDP-43 dimerizes in human cells in culture." in: Cellular and molecular neurobiology, Vol. 30, Issue 4, pp. 641-52, 2010 (PubMed). (Sample species: Human). Further details: Western Blotting

Wegorzewska, Bell, Cairns, Miller, Baloh: "TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, Issue 44, pp. 18809-14, 2009 (PubMed). (Sample species: Human). Further details: Immunohistochemistry

Geser, Brandmeir, Kwong, Martinez-Lage, Elman, McCluskey, Xie, Lee, Trojanowski: "Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis." in: Archives of neurology, Vol. 65, Issue 5, pp. 636-41, 2008 (PubMed). (Sample species: Human). Further details: Immunohistochemistry

Mackenzie, Bigio, Ince, Geser, Neumann, Cairns, Kwong, Forman, Ravits, Stewart, Eisen, McClusky, Kretzschmar, Monoranu, Highley, Kirby, Siddique, Shaw, Lee, Trojanowski: "Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations." in: Annals of neurology, Vol. 61, Issue 5, pp. 427-34, 2007 (PubMed).

Neumann, Sampathu, Kwong, Truax, Micsenyi, Chou, Bruce, Schuck, Grossman, Clark, McCluskey, Miller, Masliah, Mackenzie, Feldman, Feiden, Kretzschmar, Trojanowski, Lee: "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis." in: Science (New York, N.Y.), Vol. 314, Issue 5796, pp. 130-3, 2006 (PubMed).